GUANGDONG KANG.CO.LTD YC1 (F:E9Q) — Market Cap & Net Worth
Market Cap & Net Worth: GUANGDONG KANG.CO.LTD YC1 (E9Q)
GUANGDONG KANG.CO.LTD YC1 (F:E9Q) has a market capitalization of $19.63 Million (€16.79 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #25066 globally and #2165 in its home market, demonstrating a 0.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GUANGDONG KANG.CO.LTD YC1's stock price €0.20 by its total outstanding shares 84394000 (84.39 Million).
GUANGDONG KANG.CO.LTD YC1 Market Cap History: 2022 to 2026
GUANGDONG KANG.CO.LTD YC1's market capitalization history from 2022 to 2026. Data shows change from $17.66 Million to $19.63 Million (-4.08% CAGR).
GUANGDONG KANG.CO.LTD YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GUANGDONG KANG.CO.LTD YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of E9Q by Market Capitalization
Companies near GUANGDONG KANG.CO.LTD YC1 in the global market cap rankings as of May 5, 2026.
Key companies related to GUANGDONG KANG.CO.LTD YC1 by market ranking:
- HCA Holdings Inc (NYSE:HCA): Ranked #262 globally with a market cap of $95.53 Billion USD.
- Fresenius SE & Co. KGaA (XETRA:FRE): Ranked #970 globally with a market cap of $26.87 Billion USD ( €22.99 Billion EUR).
- FRESENIUS SE+CO. ADR 1/4 (F:FREA): Ranked #971 globally with a market cap of $26.87 Billion USD ( €22.98 Billion EUR).
- IHH Healthcare Bhd (KLSE:5225): Ranked #1289 globally with a market cap of $19.68 Billion USD ( RM78.38 Billion MYR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #262 | HCA Holdings Inc | NYSE:HCA | $95.53 Billion | $427.18 |
| #970 | Fresenius SE & Co. KGaA | XETRA:FRE | $26.87 Billion | €40.81 |
| #971 | FRESENIUS SE+CO. ADR 1/4 | F:FREA | $26.87 Billion | €10.20 |
| #1289 | IHH Healthcare Bhd | KLSE:5225 | $19.68 Billion | RM8.87 |
GUANGDONG KANG.CO.LTD YC1 Historical Marketcap From 2022 to 2026
Between 2022 and today, GUANGDONG KANG.CO.LTD YC1's market cap moved from $17.66 Million to $ 19.63 Million, with a yearly change of -4.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €19.63 Million | +21.34% |
| 2025 | €16.18 Million | -17.17% |
| 2024 | €19.54 Million | -4.81% |
| 2023 | €20.52 Million | +16.20% |
| 2022 | €17.66 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of GUANGDONG KANG.CO.LTD YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.63 Million USD |
| MoneyControl | $19.63 Million USD |
| MarketWatch | $19.63 Million USD |
| marketcap.company | $19.63 Million USD |
| Reuters | $19.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GUANGDONG KANG.CO.LTD YC1
Guangdong Kanghua Healthcare Group Co., Ltd. primarily operates private hospitals in the People's Republic of China. The company operates through four segments: Hospital Services, Rehabilitation and Other Healthcare Services, Haemodialysis Services, and Elderly Healthcare Services. It provides inpatient and outpatient healthcare, and physical examination services. The company also offers reproduc… Read more